With its remote endovascular procedure system currently under review at the FDA, Microbot Medical has put forward positive ...

Microbot Medical Inc.’s MBOT share price has surged by 15.92%, which has investors questioning if this is right time to sell.

Microbot reported positive data on its single-use endovascular robot. Elsewhere, GE Healthcare named a new business leader, ...

Microbot Medical today announced pivotal trial data supporting the use of its Liberty endovascular surgical robot.

Microbot Medical Inc., a precommercial-stage medical technology company that is developing the Liberty endovascular robotic system ...

Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of ...

Microbot Medical's (MBOT) stock gains as its Liberty surgical robotic system achieves 100% success in trials, hitting the ...

Microbot Medical (MBOT) presented for the first time the data from its ACCESS-PVI pivotal trial at the Society of Interventional Radiology ...

BRAINTREE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, is providing this reminder that data ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...